Quarterly report pursuant to Section 13 or 15(d)

License Agreements (Details)

v3.24.3
License Agreements (Details) - USD ($)
 1 Months Ended 3 Months Ended 9 Months Ended
Mar. 31, 2015
Sep. 30, 2024
Sep. 30, 2023
Sep. 30, 2024
Sep. 30, 2023
Feb. 28, 2023
Jan. 31, 2019
May 31, 2016
NeuPharma, Inc. | Additional sales milestone                
License Agreements                
Maximum potential milestone payments $ 40,000,000.0              
NeuPharma, Inc. | Clinical and development milestone                
License Agreements                
Maximum potential milestone payments 39,000,000.0              
NeuPharma, Inc. | Regulatory approvals to commercialize the products                
License Agreements                
Maximum potential milestone payments 22,500,000              
Dana-Farber Cancer Institute                
License Agreements                
Amount of milestone expensed 5,000,000.0              
Maintenance fee 50,000              
Dana-Farber Cancer Institute | First commercial sale milestone                
License Agreements                
Maximum potential milestone payments 21,500,000              
Dana-Farber Cancer Institute | Additional sales milestone                
License Agreements                
Maximum potential milestone payments $ 60,000,000.0              
Adimab, LLC | PD-L1 | Research and development                
License Agreements                
Non-Refundable milestone payment           $ 2,200,000    
Adimab, LLC | Clinical and development milestone                
License Agreements                
Maximum potential milestone payments             $ 2,500,000  
Jubilant Biosys Limited | Additional sales milestone                
License Agreements                
Maximum potential milestone payments               $ 89,300,000
Jubilant Biosys Limited | Regulatory approvals to commercialize the products                
License Agreements                
Maximum potential milestone payments               59,500,000
Jubilant Biosys Limited | Clinical development and regulatory milestones                
License Agreements                
Maximum potential milestone payments               $ 88,400,000
Collaboration Agreement With TGTX                
License Agreements                
Revenue recognition milestone revenue recognized   $ 0 $ 10,000 $ 41,000 $ 51,000      
Sublicense Agreement with TGTX                
License Agreements                
Revenue recognition milestone revenue recognized     $ 21,000   $ 45,000